Volume 8, Number 5—May 2002
Research
Excess Mortality Associated with Antimicrobial Drug-Resistant Salmonella Typhimurium
Morten Helms*, Pernille Vastrup*, Peter Gerner-Smidt*, and Kåre Mølbak*
Table 1
The distribution of comorbidity diagnosis of 2,047 patients with S. Typhimurium infection and a sample of the general Danish population of 20,456 persons
| Diagnostic group | No. (%) of S. Typhimurium patients | No. (%) in the general population | Severity score (weight) in comorbidity index |
|---|---|---|---|
| Lymphoma or leukemia | 19 (0.9) | 23 (0.1) | 3.40 |
| Metastatic cancers | 8 (0.4) | 19 (0.1) | 2.02 |
| Liver disease | 10 (0.5) | 35 (0.2) | 1.97 |
| Tuberculosis | 0 | 13 (0.1) | 1.78 |
| Movement disorders and epilepsy | 4 (0.2) | 40 (0.2) | 1.56 |
| Diabetes | 44 (2.2) | 186 (0.9) | 1.50 |
| Renal disease | 31 (1.5) | 114 (0.6) | 1.37 |
| Inflammatory bowel disease | 39 (2.4) | 66 (1.7) | 1.34 |
| Other neurologic diseasesa | 12 (0.6) | 76 (0.4) | 1.32 |
| Hemoglobin abnormalities | 14 (0.7) | 62 (0.3) | 1.23 |
| Congestive heart failure | 22 (1.1) | 103 (0.5) | 1.22 |
aNeurologic or neuromuscular diseases other than Alzheimer's disease, multiple sclerosis, Parkinson's disease, Huntington's disease, and epilepsy.
